Quercetin in the Prevention of Covid-19 Infection

• Sponsor: Azienda di Servizi alla Persona di Pavia (Other)
• Overall Status: Completed
• CT.gov ID: NCT05037240
• Collaborator: (none)
• Enrollment: 80
• Location: 1
• Arms: 2
• Actual Duration (Months): 4.4
• Patients Per Site Per Month: 18.3

Study Details

Study Description

Brief Summary

Quercetin is a flavonol, a subclass of flavonoid compounds. Of the flavonol molecules, quercetin is the most abundant in fruit and vegetables. Quercetin flavonol is characterized by 3 crucial properties: antioxidant, anti-inflammatory and immunomodulatory. The combination of these 3 properties makes quercetin an excellent candidate for dealing with situations in which oxidative stress, inflammation and the immune system are involved. The purpose of the study is to evaluate the effectiveness of an oral nutritional supplement based on quercetin in the prevention of Covid-19 infection.

Condition or Disease	Intervention/Treatment	Phase
Covid19	Dietary Supplement: Quercetin; Combination Product: Placebo	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 80 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Outcomes Assessor)
• Primary Purpose: Prevention
• Official Title: Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of an Oral Nutritional Supplement Based on Quercetin in the Prevention of Covid-19 Infection for a Duration of 3 Months
• Actual Study Start Date: Jan 12, 2021
• Actual Primary Completion Date: Apr 6, 2021
• Actual Study Completion Date: May 25, 2021

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Intervention Group	Dietary Supplement: Quercetin; Quercetin (500 mg), 2 times a day for 3 months
Placebo Comparator: Placebo	Combination Product: Placebo; 500 mg, 2 times a day for 3 months

Outcome Measures

Primary Outcome Measures

1. Prevention of Covid-19 infection [Absence of Covid-19 infection at 3 months]

   A nasopharyngeal antigenic swab

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Absence of Covid-19 infection

Exclusion Criteria:

• Previous Sars-Cov-2 infection demonstrated with antibody positivity through venous sampling

• Demonstrated presence of Sars-Cov-2 through a nasopharyngeal antigenic swab before the start of oral nutritional supplementation

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mariangela Rondanelli	Pavia		Italy	27100

Sponsors and Collaborators

• Azienda di Servizi alla Persona di Pavia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Azienda di Servizi alla Persona di Pavia
• ClinicalTrials.gov Identifier: NCT05037240
• Other Study ID Numbers: 1222/01022021
• First Posted: Sep 8, 2021
• Last Update Posted: Sep 8, 2021
• Last Verified: Sep 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: COVID-19; Quercetin

Study Results

No Results Posted as of Sep 8, 2021